Key result
Septal artery embolization with EVOH (Onyx®) reduced the left ventricular outflow tract pressure gradient to 8 mmHg and 45 mmHg at follow-up and improved symptoms in two patients with hypertrophic cardiomyopathy refractory to medical therapy.
Case Report (n=2)
No
This report describes two cases of septal artery embolization using Onyx as a percutaneous treatment for hypertrophic cardiomyopathy.
Answers are grounded in this paper and cite their sources.
May support percutaneous septal reduction in select HCM cases; leaves open need for randomized trials versus surgery.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Souza et al. (2025) conducted a case report in Hypertrophic Cardiomyopathy (n=2). Septal artery embolization with EVOH (Onyx®) was evaluated on Reduction in left ventricular outflow tract pressure gradient and symptom improvement. Septal artery embolization with EVOH (Onyx®) reduced the left ventricular outflow tract pressure gradient to 8 mmHg and 45 mmHg at follow-up and improved symptoms in two patients with hypertrophic cardiomyopathy refractory to medical therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: